

CHARACTERIZATION OF CYCLODEXTRINS COMPLEXES WITH POORLY SOLUBLE DRUGS IN SOLUTION AND SOLID STATE

N. Galić,^a M. Pocrnić,^a D. Klarić,^a A. Čikoš,^b A. Budimir,^c M. Hoelm,^d M. Jug^c

^a Department of Chemistry, Faculty of Science, University of Zagreb, Zagreb, Croatia

^b Ruđer Bošković Institute, Zagreb, Croatia

^c Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia

^d Faculty of Chemistry, University of Lodz, Lodz, Poland

✉ ngalic@chem.pmf.hr

The solubility of poorly soluble drugs can be improved by complexation with β -cyclodextrin and its derivatives. The drug-cyclodextrin complexes in the solution and in the solid state are usually characterized by different methods, including UV-Vis, fluorescence, MS, NMR, DSC, IR etc.^{1,2} The complexation of loratadine (LOR) and nabumetone (NAB) complexes with β -cyclodextrins (β -CD) and its derivatives (hydroxypropyl β -CD (HP- β -CD), randomly methylated β -CD (RM- β -CD) and sulfobutylether β -CD sodium salt (SBE- β -CD)) was studied by means of an integrated approach comprising ITC, MS, NMR spectroscopy, DSC, PXRD, ATR-FTIR, and computational methods.³⁻⁵ The formation of inclusion complexes was confirmed both in solid state and in the solution, resulting with improved solubility of abovementioned poorly soluble drugs. The stoichiometry, mode of binding, and thermodynamic parameters for complexes were determined.




Figure 1. Structures of loratadine, nabumetone and β -cyclodextrins

Acknowledgements. This work has been supported by Croatian Science Foundation under the project number HRZZ-IP-2022-10-6033.

REFERENCES

- [1] P. Mura, J. Pharm. Biomed. Anal. **2014**, 101, 238-250.
- [2] P. Mura, J. Pharm. Biomed. Anal. **2015**, 113, 226-238.
- [3] M. Pocrnić, M. Hoelm, A. Ignaczak, A. Čikoš, A. Budimir, V. Tomišić, N. Galić, J. Mol. Liquid. **2024**, 410, 125515.
- [4] D. Klarić, M. Kelrajter, A. Čikoš, A. Budimir, N. Galić, J. Mol. Liquid. **2024**, 397, 124152.
- [5] D. Klarić, Ž. Soldin, A. Vincze, R. Szolláth, G. T. Balogh, M. Jug, N. Galić, Pharmaceutics **2024**, 16, 1493.